drugset

drugset / Trial / NCT00427440

A Phase II Study to Treat Advanced Malignant Glioma

NCT00427440 ↗

Phase 2 Completed 61 enrolled Amgen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.

Timeline

Start: 2006-11
Primary completion: 2008-12
Completion: 2013-04

Publications

Background Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr;13(4):437-46. doi: 10.1093/neuonc/noq198. Epub 2011 Feb 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rilotumumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Rilotumumab	Monoclonal antibody	20 mg/kg	Intravenous

Indications